Renal & Urology NewsCognitive vs Software-Fusion Biopsy Noninferior for Prostate Cancer Detection

✅ Clinical Decision Support / Validated Tool

MRI-targeted prostate biopsy can be performed using either cognitive fusion or software-assisted image registration, although software platforms require additional equipment and training. The IMAGINATION trial evaluated whether the less resource-intensive cognitive approach could achieve comparable detection of clinically significant prostate cancer.

Clinical Considerations

• Clinically significant prostate cancer was detected in 32% of cognitive fusion patients versus 34% undergoing software-based fusion.
• Cognitive fusion met the prespecified 10% noninferiority margin in intention-to-treat analysis.
• Detection rates remained comparable across per-protocol, best-case, and worst-case analyses.
• BMI significantly influenced performance, with cognitive fusion favored in leaner men and software fusion favored in men with BMI at or above 24 kg/m².

Practice Applications

• Consider cognitive fusion biopsy where software platforms are unavailable.
• Interpret noninferiority findings within the context of operator expertise.
• Recognize BMI as a potential factor when selecting biopsy approaches.
• Monitor applicability of these findings in Western populations and broader practice settings.